Sewoon Medical Co. Ltd (100700) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Sewoon Medical Co. Ltd stock KRW 5,541, price KRW 2,255, upside +145.7%, quality 76 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 2,075 KRW – 5,438 KRW · fair‑value band 4,540 KRW – 6,353 KRW · the 2,255 KRW price screens below the 5,541 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Sewoon Medical Co. in your weekly email
Every Wednesday you see whether Sewoon Medical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sewoon Medical Co., Ltd. engages in the research and development, manufacture, and sale of medical products. Its products include wound drainage systems, urinary catheters and tubes, drainage catheters and tubes, respiratory and tracheal tubes, infusion catheters and tubes, and wound care products.
Show moreShow less
The company also offers unigel, thermosens, epistim, bonastent, and other products. Sewoon Medical Co., Ltd. was founded in 1982 and is headquartered in Cheonan, South Korea.
Stock analysis
Sewoon Medical Co. Ltd (100700) currently trades at 2,255 KRW, while our model-based Fair Value estimate is 5,541 KRW, implying the stock looks roughly 59% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 6,054 KRW per share, and 22 of the 24 models we run sit above the 2,255 KRW price.
Bear case: the Asset-Based group reads lowest at 2,690 KRW, and 2 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 4,540 KRW (bear) to 6,353 KRW (bull), the price of 2,255 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 76/100 (high quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Sewoon Medical Co. Ltd reported revenue of 63.7B KRW in FY2025 versus 62.6B KRW in FY2021, a compound +0.4%/yr. Reported net income was 11.9B KRW in FY2025, compounding −0.8%/yr from FY2021.
Key figures
Market cap 95.1B KRW (≈ $70.3M) Micro · P/S ratio 1.63 · Dividend yield 2.5% · Net margin 17.9% · Return on equity 789% · Return on assets (EBIT) 9.6% (5-year average) · Operating margin 21.2% · Revenue (TTM) 60.3B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 66 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 146%, 100700 screens cheaper than that median.
Fair Value models
Bear4,540 KRWFair Value 5,541 KRWBull6,353 KRW
Price 2,255 KRW · Upside +145.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+5.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.0%
Start year 2020 (pandemic). Over 10 years: +1.3% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+5.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.1%
Dividend (yield on the price)2.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3.1% vs 3.9%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 20%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)Health Care · 2276 stocks
Beats the sector median on 9/10 measures
Overall it ranks above its sector peers.
Valuation
Quality Score76 · Top 25%
Fair Value upside+145.7% · Top 25%
Profitability
Return on assets7.3% · Top 25%
Net margin (12 months)17.9% · Top 25%
Operating margin (12 months)21.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−5.2% · Bottom 25%
Dividend yield (12 months)2.5% · Above median
Valuation Multiplesvs Health Care median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sewoon Medical Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/100700
Frequently asked questions
Is Sewoon Medical Co. Ltd (100700) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 5,541 KRW versus a price of 2,255 KRW, about +146% upside (undervalued).
What is the fair value of 100700?
Our model-based fair value for Sewoon Medical Co. Ltd is 5,541 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 2,255 KRW.
What is the quality score of 100700?
Sewoon Medical Co. Ltd has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sewoon Medical Co. Ltd (100700)?
Our model-based price target is the fair value of 5,541 KRW (as of Nov 9, 2026) from 24 valuation models. Cautious scenario 4,540 KRW, optimistic scenario 6,353 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Sewoon Medical Co. Ltd stock forecast for 2026?
Our models put fair value at 5,541 KRW, about +146% upside versus a price of 2,255 KRW (undervalued). Cautious scenario 4,540 KRW, optimistic scenario 6,353 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Sewoon Medical Co. Ltd (100700)?
Sewoon Medical Co. Ltd reported trailing-twelve-month revenue of about 60.3B KRW (latest available figure, as of Nov 9, 2026).
Does Sewoon Medical Co. Ltd pay a dividend?
Sewoon Medical Co. Ltd currently shows a dividend yield of 2.46% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Sewoon Medical Co. Ltd (100700)?
Sewoon Medical Co. Ltd has a dividend yield of 2.5%. A dividend has been paid every year since at least 2008. Our assessment: Safety not assessed. Payout ratio and cash coverage are not available, so we do not judge how safe this dividend is.
What growth is priced into Sewoon Medical Co. Ltd (100700)?
For today's price to be fair in a discounted-cash-flow model, Sewoon Medical Co. Ltd would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 0.0 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 100700 use?
Our models discount Sewoon Medical Co. Ltd at 13.1 %: a base by market capitalisation (micro), damped by beta 0.98, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sewoon Medical Co. Ltd that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has Sewoon Medical Co. Ltd (100700) delivered so far?
Over the past 5 years revenue at Sewoon Medical Co. Ltd grew 0.0 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sewoon Medical Co. Ltd (100700) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Sewoon Medical Co. Ltd (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sewoon Medical Co. Ltd (100700)?
The free-cash-flow yield on the price is 16.90 %: that much free cash flow Sewoon Medical Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sewoon Medical Co. Ltd (100700)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sewoon Medical Co. Ltd it is 5,541 KRW per share (as of Nov 9, 2026), against a price of 2,255 KRW. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Sewoon Medical Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 100700 trades below its calculated fair value: price 2,255 KRW, fair value 5,541 KRW, a gap of about +146% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 100700?
No. The price is what the market pays today (2,255 KRW); the fair value is what the company's own numbers justify (5,541 KRW). For Sewoon Medical Co. Ltd the two are 3,286 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Sewoon Medical Co. Ltd worth?
The market values Sewoon Medical Co. Ltd at about 95.1B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 2,255 KRW; our models calculate a fair value of 5,541 KRW per share.
What do the bullish and bearish scenarios say about 100700?
Our models span a range for Sewoon Medical Co. Ltd: cautious scenario 4,540 KRW, base 5,541 KRW, optimistic 6,353 KRW per share (as of Nov 9, 2026, price 2,255 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 100700 from its 52-week high?
Sewoon Medical Co. Ltd trades at 2,255 KRW, about 26% below its 52-week high of 3,035 KRW and 9% above the low of 2,075 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 5,541 KRW is for.
Which stocks are comparable to Sewoon Medical Co. Ltd?
From the same area (Healthcare) we also value InBody Co, Value Added Technology Co, Mediana Co, Meta Biomed Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sewoon Medical Co. Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 2,255 KRW, calculated fair value 5,541 KRW (+146%), Quality Score 76/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 100700 calculated?
We run Sewoon Medical Co. Ltd through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5,541 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sewoon Medical Co. Ltd currently trades 59% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sewoon Medical Co. Ltd (100700)?
The closing price on Nov 6, 2026 was 2,255 KRW. Our model-based fair value is 5,541 KRW, about +146% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sewoon Medical Co. Ltd right now?
The rarer combination: high quality (76/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (4,540 KRW). The market is more pessimistic than our downside scenario.
Key figures of Sewoon Medical Co. Ltd
How large is the market capitalisation of Sewoon Medical Co. Ltd (100700)?
The market capitalisation of Sewoon Medical Co. Ltd is 95.1B KRW (≈ $70.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sewoon Medical Co. Ltd (100700)?
The price-to-sales ratio of Sewoon Medical Co. Ltd is 1.63 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Sewoon Medical Co. Ltd (100700)?
The dividend yield of Sewoon Medical Co. Ltd is 2.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sewoon Medical Co. Ltd (100700)?
The net margin of Sewoon Medical Co. Ltd is 17.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sewoon Medical Co. Ltd (100700)?
The return on equity (ROE) of Sewoon Medical Co. Ltd is 789% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sewoon Medical Co. Ltd (100700)?
On an EBIT basis the return on assets of Sewoon Medical Co. Ltd is 9.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sewoon Medical Co. Ltd (100700)?
The operating margin of Sewoon Medical Co. Ltd is 21.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sewoon Medical Co. Ltd (100700)?
Revenue at Sewoon Medical Co. Ltd is growing −5.2% versus a year earlier (3y avg +1.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sewoon Medical Co. Ltd (100700)?
Earnings per share at Sewoon Medical Co. Ltd are growing −11.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Sewoon Medical Co. Ltd in the live analysis
One click puts Sewoon Medical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026